argenx

argenx

生物技术研究

Boston,MA 71,129 位关注者

United in our commitment to improve the lives of patients

关于我们

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

网站
https://www.argenx.com
所属行业
生物技术研究
规模
1,001-5,000 人
总部
Boston,MA
类型
上市公司
创立
2008
领域
Oncology、Autoimmune diseases、Rare Diseases、Antibody based medicines、Immunotherapy、Myasthenia Gravis、Immunology、Pemphigus Vulgaris、Immune Thrombocytopenia、Acute Myeloid Leukemia 、high-risk myelodysplastic syndromes和chronic inflammatory demyelinating polyneuropathy

地点

argenx员工

动态

相似主页

查看职位

融资

argenx 共 10 轮

上一轮

上市后股权

US$1,097,641,460.00

Crunchbase 上查看更多信息